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Abstract
Tektrotyd kit was developed by Polatom company for 99mTc labeling to make an alternative tracer of somatostatin receptor 
scintigraphy available. Since 2005, 99mTc-EDDA/HYNIC-Tyr3-Octreotide has been used in clinical imaging and achieved high 
impact in management of patients with neuroendocrine tumors. Knowing the limitations and pitfalls is essential to provide ac-
curate diagnosis. Therefore, the potential pitfalls associated with the use of 99mTc-EDDA/HYNIC-TOC are reviewed on the basis 
of own experience. 
Data were analyzed of 310 patients who underwent somatostatin receptor scintigraphy with 99mTc-Tektrotyd. Pitfalls during 
radiolabeling process or acquisition can worsen the sensitivity of SRS (somatostatin receptor scintigraphy). Recognizing physi-
ological and clinical pitfalls, the diagnostic accuracy will improve. 
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Introduction
Diagnosed incidence of neuroendocrine tumors (NETs) is pre-
dicted to continuously rise at a faster rate than other malignant neo-
plasms [1]. NETs are heterogeneous groups of tumors originating 
from different organs including lungs, pancreas, gastrointestinal 
tract etc. The common characteristic of these tumors is the ability 
to produce peptides. The primary diagnosis of NET is difficult and 
late because of general symptoms, tumor heterogeneity and a wide 
range of origin of the tumor. The cornerstone of the diagnosis of NET 
was the development of various radiolabeled somatostatin ana-
logs and the introduction of SPECT/CT in clinical work. Fortunately 
the radiolabeled somatostatin analogs generate the possibility of 
targeted biological therapy, which offers these patients improved 
progression-free survival and often better quality of life. Soma-
tostatin receptor scintigraphy is the best option for detection of 
well differentiated NETs, and classifies the patients based on their 
somatostatin receptor density. Many radiolabeled somatostatin 
analogs are available for human use. These radiopharmaceutical 
scans differ in radionuclides, chelators and the affinity to different 
subtypes of somatostatin receptors (SSTR). Therefore sensitivity 
and specificity may differ. The most frequently used radiotrac-
ers are 111In- and 99mTc labeled pharmaceuticals for SPECT imag-
ing. Since 2013, 99mTcEDDA/HYNIC-Tyr3-Octreotide (Tektrotyd, 
Polatom) has been used at our Institute for somatostatin receptor 
scintigraphy. In this study we summarized our experience based 
on more than 300 patients’ examinations focusing on limitation and 
potential pitfalls in the use of 99mTc-EDDA/HYNIC-Tyr3-Octreotide in 
routine clinical practice.
Material and methods
Since 2013, we have performed 310 patients’ examina-
tions with 99mTc-EDDA/HYNIC-Tyr3-Octreotide (Tektrotyd, Polatom) 
to assess somatostatin receptor expression in neuroendocrine 
tumors. The majority of the patients’ neuroendocrine tumor diag-
nosis was proven by histology, but in some cases we tried to find 
the origin of the primary tumor. The main clinical question was to 
select candidates for therapy with somatostatin analogs or to 
evaluate its effectiveness. Well-hydrated condition, light food intake 
and mild laxatives are recommended before the examination, espe-
cially when the abdomen is the area of interest. If the patient is on 
somatostatin analog therapy, it is required to discontinue taking 
medication for six weeks. In our practice 500–600 MBq99mTcEDDA/ 
/HYNIC-Tyr3-Octreotide was injected intravenously. Radiolabeling 
is easy to perform, but the preparation of the radiopharmaceutical 
should begin one hour before the time of planned injection.
Acquisition protocol
Early (1 hour after injection) and late (4 hours after injection) 
whole body scans were performed with two headed large field 
of view gamma camera equipped with LEHR (low energy high 
resolution) collimator (AnyscanSC, Mediso) based on the following 
acquisition protocol: Whole body scan was done in the anterior and 
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posterior projections (256 x 1024 matrix, 13 cm/min). After 4 hours, 
whole body scan SPECT/CT was made about the questionable 
region with the following parameters: 360° noncircular orbit (body 
contour mode) step and shoot mode, at 30 s per view. The acquired 
data were collected in a 128 x 128 image matrix, reconstructed 
using filtered back projections with a Butterworth filter (cut-off 0.6 
cycles/pixel, order 5). 
Radiolabeling
In our daily routine production we get radiochemical yields (RCY) 
between 96.5 and 98.9% which is far above the 90% limit. To achieve 
these results we have to keep the exact orders during the production 
steps otherwise the specific activity and the RCY can significantly 
decrease. Several circumstances could affect the labeling proce-
dure but there is only one which requires more attention. 
The reaction temperature must be at 80°C for 20 min incubation 
to reach the efficient RCY. It is important to maintain the temperature 
at the optimum. Nevertheless, keeping the rule of radiolabeling pro-
cess the efficacy of radiolabeling and in vitro stability of this tracer 
supports comfortable use in daily practice [2].
Technical considerations and improved diagnostic 
accuracy
The 111In labeled somatostatin analog 111In-DTPA-D-Phe1-Octre-
otide has been most frequently used worldwide so far. Development 
of 99mTc-labeled somatostatin compounds was a real appreciation 
of necessity, because of better physical characteristics of 99mTc. 
99mTc is more suitable for gamma camera imaging, providing 
higher resolution and better image quality with lower radiation dose. 
99mTc-EDDA/HYNIC-Tyr3-Octreotide results in higher tumor/back-
ground ratios than the 111In tracers, especially in relation to heart 
and muscle. Significantly more lesions could be detected in 99mTc 
images [3]. Tomographic images are required especially about the 
region of interest to improve sensitivity and detection. Furthermore, 
hybrid technology (SPECT/CT) is also desirable providing anatomi-
cal information to precisely localize pathological uptake. The higher 
resolution of 99mTcEDDA/HYNIC-Tyr3-Octreotide images results in 
better registration on SPECT/CT increasing better lesion localiza-
tion in contrast to111In octreotide. Attenuation correction should be 
considered especially in overweight patients to improve sensitivity 
resulting in higher diagnostic accuracy. Furthermore, CT scan 
provides the possibility of quantitative analysis due to advanced 
level of reconstruction methods (Figure 1). 
Physiological distribution of 99mTc-EDDA/HYNIC-Tyr3- 
-Octreotide and physiological pitfalls
Physiologic distribution of Tektrotyd reflects the specific and 
non-specific binding and excretion pattern. 99mTc-Tektrotyd is ex-
creted mainly by the kidneys with a small contribution of hepatic 
excretion. Cumulative urine excretion within 24h falls in the range 
of 24–64% of the administered dose. However, kidney uptake of 
99mTc-EDDA/HYNIC-Tyr3-Octreotide is more complex due to the 
fact that specific and high-affinity SSTR have also been identified 
in the human kidney. In the cortex, these receptors are located 
in the proximal tubules and in the medulla in the medullary vasa 
recta based on autoradiographic results. These receptors pro-
bably belong to SSR2 subtypes causing high specific binding on 
octreotide scans besides excretion. Accordingly, the kidneys are 
the most jeopardized organs for radiation and radiation protection 
during targeted radionuclide therapy and diagnostic procedure 
is important. 
Because of hepatic excretion, physiological gallbladder uptake 
is rarely seen especially on late images under fasting condition. 
Faint to moderate bowel activity is also visible especially on late 
scans too (Figure 2).
Uptake in salivary glands, thyroid, pituitary gland, and spleen 
is mediated by the expression of SSTR with different densities of 
receptor subtypes. Endocrine organs, gastrointestinal tract and the 
human lymphatic tissue represent some of the important sites of 
SSTR expression in the human body observed with in vitro receptor 
autoradiography [4]. Several lymphatic tissues contain SSTR includ-
ing thymus, spleen and gut associated lymphatic tissue consisting 
mainly of activated lymphocytes. The majority of the SSTR in the 
lymphatic organs belongs to the SSTR2 subtype, as they can bind 
radiolabeled somatostatin analogs with high affinity. Recognizing 
these patterns is essential to differentiate normal variants from 
pathological ones. The most frequently occurring physiological va-
riants were focal accumulation in the head of the pancreas (1–2%), 
Figure 1. A 67-year-old female patient with a history of histologically proved small-cell lung cancer expressing somatostatin receptors. On NAC 
(non-attenuation correction) MIP (maximal intensity projection) image (A) slight, uncertain uptake was revealed in the mediastinum, but on AC 
(attenuation correction) MIP image (B) intense uptake was found in that area resulting in higher target signal to noise ratio. After removal of this 
pathologic lymph node the histological analysis proved the diagnosis of somatostatin receptor positive metastasis
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associated spleen or splenosis (< 2%) and focal pulmonary uptake 
without morphological pattern (2.5%) in our cases. 
Prominent pancreatic uncinate process accumulation is visible 
in few percent of patients. Without additional morphology, it is dif-
ficult to differentiate from malignant pancreatic process. SPECT/CT 
can help us to assess normal anatomy in the background of the 
accumulation. Because of the poor tissue resolution of low dose 
CT without contrast, further examination — multiphase CT or MRI 
— sometimes is required for accurate diagnosis (Figure 3).
Splenectomy is often carried out in patients with pancreatic tail 
NET tumors and splenosis is a common finding in these cases. 
Focal or multiple, round-like or sometimes irregular soft tissue 
activity is visible on SPECT/CT in the splenic bed. Diagnosis can 
be mistaken for mesenteric metastasis. In uncertain cases, spleen 
scintigraphy with radiolabeled colloids or denatured red blood 
cells can help in diagnosis (Figure 4). 
Nevertheless in patients with normal spleens, an accessory 
spleen is visible on the scan, but the activity of this tissue is com-
parable with the normal splenic activity and rarely causes differential 
diagnostic problem. 
An interesting finding on somatostatin receptor scintigraphy 
was a solitaire or multiple focal intense uptake in the lungs without 
any morphological abnormality. There was a case of a young man 
with a history of neuroendocrine tumor who was operated because 
of findings of focal intense uptake in his lung, but histological 
analysis could not prove the malignancy. Only bronchiectasia, ma - 
crophages and lymphocytes were found in the sample (Figure 5). We 
suppose that focal bronchitis or bronchiolitis can cause such a sign. 
Activated lymphocytes and macrophages can express SSTR2 
with higher density and Varecza et al. proved in their experimental 
studies that SSTR4 expression is higher both in subacute and 
chronic inflammatory reactions in the lungs including smoking sub-
jects as well. They found a large number of SSTR-positive activated 
macrophages and some lymphocytes in alveoli of chronic inflamed 
lungs. However, 99mTc-HYNIC-Tyr3-Octreotide binds with high affini-
ty to SSTR2 and with low affinity to SSTR3 and SSTR5. This sign 
is likely the result of complex pathophysiology [5, 6]. Increased 
radiopharmaceutical uptake is frequently seen in lungs after ra-
diotherapy, but in that case fibrotic-infiltrative changes are also 
visible on SPECT/CT. 
Figure 2. Intense physiological tracer uptake was seen in the bowel on 99mTc-Tektrotyd SPECT/CT
Figure 3. Focal intense uptake was seen in pancreatic head, without 
morphological abnormality, due to physiologic accumulation of 
pancreatic uncinate process
Figure 4. A 58-year-old patient with a history of pancreatic 
neuroendocrine tumor. The splenectomy was performed and in the 
splenic bed a small soft tissue mass showed increased uptake of 
99mTc-Tektrotyd, which represents a remnant spleen tissue




99mTc-EDDA/HYNIC-Tyr3-Octreotide demonstrated rapid tissue 
uptake within the first hour after injection and without significant 
clearance from normal or tumor tissue up to 20h p.i. In contrast, 
continuous clearance is detected from normal tissues as well 
as renal and hepatobiliary excretion using 111In-DTPA-Octreotide 
[7]. SSTR-positive lesions showed intense tracer accumulation 
because of high in vivo stability and quick background clearance of 
99mTc-EDDA/HYNIC-Tyr3-Octreotide. However, somatostatin receptor 
scintigraphy has lower sensitivity for lesions that are present in or-
gans having physiological tracer concentration such as the liver. The 
detection rate can be improved by SPECT/CT (Figure 6). Furthermore, 
receptor density can change due to dedifferentiation of tumor or after 
therapy causing inhomogeneous appearance of the tumor on SRS. 
Increased uptake of 99mTc-EDDA/HYNIC-Tyr3-Octreotide 
sometimes appears in benign lesions representing higher expres-
sion of somatostatin receptors. Osteoblasts express SSTR2 and 
thus degenerative bone disease, fractures, and epiphyseal growth 
plates in children can show increased activity on SRS (Figure 7) [8]. 
Furthermore, parathyroid adenoma and inflammatory processes in 
different organs, such as colitis, prostatitis, and thyroiditis, also 
accumulate radiolabeled somatostatin analogs causing false 
positive results [9].
Sometimes the incidental uptake on SRS was found unlikely 
to the neuroendocrine origin. We have to take into consideration 
that not only neuroendocrine tumors express somatostatin recep-
tors with high density. Other tumors like meningioma, breast cancer, 
lymphoma, and prostatic cancer can express SSTR resulting in 
increased uptake on SRS (Figures 8 and 9) [10]. 
Conclusion
Somatostatin receptors (SSTR) were identified in various nor-
mal human tissues, as well as in several types of human tumors, 
Figure 5. Intense focal accumulation in the upper lobe of right lung on 
SPECT/CT (A) without morphologic abnormality on CT (B)
Figure 6. On whole-body scan the tracer distribution of liver seemed 
homogenous (A), but on SPECT/CT, a focal intense 99mTc-Tektrotyd 
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especially neuroendocrine ones. SRS imaging in neuroendocrine 
tumors is useful for the primary diagnosis, staging of the disease, se-
lecting patients for targeted therapy, and monitoring its efficacy [11].
Recognizing potential pitfalls and limitations using radiolabeled 
somatostatin analogs can improve our diagnostic confidence. 111In 
labeled somatostatin analog is the commonly used tracer and ma-
jority of the published literature have been done using this tracer. In 
studies, the sensitivity of SRS varies for different subtypes of NETs to 
be between 50 and 95% [12]. Because 111In has longer half-life, 
and higher energy of emitted gamma rays, 99mTc labeled agent 
for somatostatin receptor imaging has gained ground for SPECT 
imaging. The pharmacokinetic properties of 99mTc-EDDA/HYNIC 
TOC were found to be better than those of 111In-Octreotide. Higher 
target-to-non-target ratios and higher absolute tumor uptake va-
lues were observed for 99mTc-EDDA/HYNIC TOC and the optimal 
acquisition time for imaging was identified as 4 hours after injec-
tion. The potential competitors of 99mTc radiolabeled somatostatin 
analogs are 68Ga labeled compounds providing higher resolution 
using PET imaging [13]. Nevertheless, 99mTc labeled somatostatin 
analogs still remain a sensitive and cost effective method in imaging 
of neuroendocrine tumors. 
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